Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

OCTA-C1-INH

Phase 3Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Hereditary Angio EdemaRecruiting

Acute Hereditary Angio EdemaPhase 3

Recruiting

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Acute Hereditary Angio Edema

NCT06361537

Clinical

Trials by Indication[1]

Acute Hereditary Angio Edema1 trial

Prospective, Multicenter, Randomized, Double-blind, Parallel Group, Placebo- Controlled, Efficacy and Safety Phase 3 Study of an Intravenous Human Plasma- Derived C1 Esterase Inhibitor (C1-INH) Concentrate in Participants With Congenital C1-INH Deficiency for the Treatment and Pre-procedure Prevention of Acute Hereditary Angioedema Attacks

Recruiting· Octapharma logo

Octapharma·Phase 3·NCT06361537·124 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OCTA-C1-INH. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OCTA-C1-INH compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OCTA-C1-INH. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Octapharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Octapharma

Related News